原发性胆汁性胆管炎的免疫遗传研究现状

马伟煜; 邓志华

doi:10.3969/j.issn.1001-5256.2020.04.050

原发性胆汁性胆管炎的免疫遗传研究现状

DOI: 10.3969/j.issn.1001-5256.2020.04.050

山西医科大学第二医院消化内科

详细信息

中图分类号: R575.7
计量
- 文章访问数: 1007
- HTML全文浏览量: 49
- PDF下载量: 205
- 被引次数: 0
出版历程
- 出版日期: 2020-04-20

Current status of immunogenetic studies on primary biliary cholangitis

Department of Gastroenterology, The Second Hospital of Shanxi Medical University

摘要

摘要: 原发性胆汁性胆管炎(PBC)的病理特征是免疫介导的小胆管上皮细胞凋亡性坏死所导致的进行性肝内胆汁淤积,具有进展为胆管纤维化、肝硬化和肝细胞癌的风险。PBC具有免疫遗传特性,PBC患者免疫应答的遗传调控异常包括人类白细胞抗原(HLA)和非HLA基因参与的、以肝内小胆管上皮细胞线粒体内的丙酮酸脱氢酶复合体E2亚基为抗原的T、B淋巴细胞免疫应答异常。超过30%的PBC患者对熊去氧胆酸治疗反应差,因此明确PBC免疫调控异常的机制对PBC免疫治疗具有广泛临床指导意义。
- 原发性胆汁性胆管炎 /
- 基因 /
- 免疫 /
- HLA抗原
Abstract: Primary biliary cholangitis( PBC) has the pathological feature of progressive intrahepatic cholestasis caused by immune-mediated apoptotic necrosis of small biliary epithelial cells,with a risk of progression to bile duct fibrosis,liver cirrhosis,and hepatocellular carcinoma. PBC has immunogenetic characteristics,and the abnormal genetic regulation of immune response in patients with PBC includes abnormal immune response of T and B lymphocytes involving human leukocyte antigen( HLA) and non-HLA genes and taking pyruvate dehydrogenase complex-E2 in mitochondria of intrahepatic small biliary epithelial cells as the antigen. More than 30% of PBC patients have poor response to ursodeoxycholic acid treatment,and therefore,clarifying the mechanism of abnormal immune regulation in PBC has great clinical significance in guiding the immunotherapy for PBC.
- primary biliary cholangitis /
- gene /
- immunity /
- HLA antigens

HTML全文

参考文献(34)

[1] BEUERS U,GERSHWIN ME,GISH RG,et al. Changing nomenclature for PBC:From ‘cirrhosis’to ‘cholangitis’[J].Hepatology,2015,62(5):1620-1622.

[2] INVERNIZZI P,RANSOM M,RAYCHAUDHURI S,et al. Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis[J]. Genes Immun,2012,13(6):461-468.

[3] ZHAO DT,LIAO HY,ZHANG X,et al. Human leucocyte antigen alleles and haplotypes and their associations with antinuclear antibodies features in Chinese patients with primary biliary cirrhosis[J]. Liver Int,2014,34(2):220-226.

[4] UMEMURA T,JOSHITA S,ICHIJO T,et al. Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis[J].Hepatology,2012,55(2):506-511.

[5] LIU JZ,ALMARRI MA,GAFFNEY DJ,et al. Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis[J]. Nat Genet,2012,44(10):1137-1141.

[6] LLEO A,MARZORATI S,ANAYA JM,et al. Primary biliary cholangitis:A comprehensive overview[J]. Hepatol Int,2017,11(6):485-499.

[7] CHOW IT,JAMES EA,GATES TJ,et al. Differential binding of pyruvate dehydrogenase complex-E2 epitopes by DRB1*08∶01and DRB1*11∶01 Is predicted by their structural motifs and correlates with disease risk[J]. J Immunol,2013,190(9):4516-4524.

[8] DARLAY R,AYERS KL,MELLS GF,et al. Amino acid residues in five separate HLA genes can explain most of the known associations between the MHC and primary biliary cholangitis[J]. PLo S Genet,2018,14(12):e1007833.

[9] WANG C,ZHENG X,JIANG P,et al. Genome-wide association studies of specific antinuclear autoantibody subphenotypes in primary biliary cholangitis[J]. Hepatology,2019,70(1):294-307.

[10] KAR SP,SELDIN MF,CHEN W,et al. Pathway-based analysis of primary biliary cirrhosis genome-wide association studies[J]. Genes Immun,2013,14(3):179-186.

[11] WEBB GJ,HIRSCHFIELD GM. Using GWAS to identify genetic predisposition in hepatic autoimmunity[J]. J Autoimmun,2016,66:25-39.

[12] GULAMHUSEIN AF,JURAN BD,LAZARIDIS KN. Genomewide association studies in primary biliary cirrhosis[J]. Semin Liver Dis,2015,35(4):392-401.

[13] LI P,LU G,CUI Y,et al. Association of IL12A expression quantitative trait loci(e QTL)with primary biliary cirrhosis in a chinese han population[J]. Medicine(Baltimore),2016,95(19):e3665.

[14] WASIK U,WUNSCH E,NORMAN GL,et al. Polymorphisms of IL12RB2 may affect the natural history of primary biliary cholangitis:A single centre study[J]. J Immunol Res,2017,2017:2185083.

[15] JOSHITA S,UMEMURA T,NAKAMURA M,et al. STAT4 gene polymorphisms are associated with susceptibility and ANA status in primary biliary cirrhosis[J]. Dis Markers,2014,7:727393.

[16] YANG XC,FUJINO M,CAI SJ,et al. Genetic polymorphisms of cytotoxic T-lymphocyte antigen 4 in primary biliary cholangitis:A meta-analysis[J]. J Immunol Res,2017,11:1-12.

[17] LI Q,WANG B,PAN F,et al. Association between cytotoxic Tlymphocyte antigen 4 gene polymorphisms and primary biliary cirrhosis in Chinese population:Data from a multicenter study[J]. J Gastroenterol Hepatol,2013,28(8):1397-1402.

[18] ESKANDARI-NASAB E,TAHMASEBI A,HASHEMI M. Meta-analysis:The relationship between CTLA-4+49 A/G polymorphism and primary biliary cirrhosis and type I autoimmune hepatitis[J]. Immunol Invest,2015,44(4):331-348.

[19] NAKAMURA M,NISHIDA N,KAWASHIMA M,et al. Genomewide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population[J]. Am J Hum Genet,2012,91(4):721-728.

[20] HITOMI Y,KAWASHIMA M,AIBA Y,et al. Human primary biliary cirrhosis-susceptible allele of rs4979462 enhances TNFSF15 expression by binding NF-1[J]. Hum Genet,2015,134(7):737-747.

[21] SUN Y,IRWANTO A,TOYO-OKA L,et al. Fine-mapping analysis revealed complex pleiotropic effect and tissue-specific regulatory mechanism of TNFSF15 in primary biliary cholangitis,Crohn’s disease and leprosy[J]. Sci Rep,2016,6:31429.

[22] MELLS GF,FLOYD JA,MORLEY KI,et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis[J]. Nat Genet,2011,43(4):329-332.

[23] TANAKA A,INVERNIZZI P,OHIRA H,et al. Replicated association of 17q12-21 with susceptibility of primary biliary cirrhosis in a Japanese cohort[J]. Tissue Antigens,2011,78(1):65-68.

[24] HITOMI Y,KOJIMA K,KAWASHIMA M,et al. Identification of the functional variant driving ORMDL3 and GSDMB expression in human chromosome 17q12-21 in primary biliary cholangitis[J]. Sci Rep,2017,7(1):2904.

[25] LI Y,WANG W,TANG L,et al. Chemokine(C-X-C motif)ligand 13 promotes intrahepatic chemokine(C-X-C motif)receptor 5+lymphocyte homing and aberrant B-cell immune responses in primary biliary cirrhosis[J]. Hepatology,2015,61(6):1998-2007.

[26] QIU F,TANG R,ZUO X,et al. A genome-wide association study identifies six novel risk loci for primary biliary cholangitis[J]. Nat Commun,2017,8:14828.

[27] HITOMI Y,NAKATANI K,KOJIMA K,et al. NFKB1 and MANBA confer disease susceptibility to primary biliary cholangitis via independent putative primary functional variants[J]. Cell Mol Gastroenterol Hepatol,2019,7(3):515-532.

[28] CARBONE M,LLEO A,SANDFORD RN,et al. Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis[J]. Eur J Immunol,2014,44(4):945-954.

[29] KAWASHIMA M,HITOMI Y,AIBA Y,et al. Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population[J]. Hum Mol Genet,2017,26(3):650-659.

[30] XIA ZY,HAN T,MENG HJ. Clinical effect of early-stage immunosuppression combined with ursodeoxycholic acid in treatment of primary biliary cirrhosis[J]. Clin J Med Offic,2020,48(1):97-98,101.(in Chinese)夏志勇，韩涛，孟红军．早期免疫抑制联合熊去氧胆酸治疗原发性胆汁性肝硬化临床疗效[J]．临床军医杂志，2020,48(1):97-98,101.

[31] RAUTIAINEN H,KARKKAINEN P,KARVONEN AL,et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:A three-year randomized trial[J]. Hepatology,2005,41(4):747-752.

[32] HIRSCHFIELD GM,GERSHWIN ME,STRAUSS R,et al. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid:A proof-of-concept study[J]. Hepatology,2016,64(1):189-199.

[33] BOWLUS CL,YANG GX,LIU CH,et al. Therapeutic trials of biologics in primary biliary cholangitis:An open label study of abatacept and review of the literature[J]. J Autoimmun,2019,101:26-34.

[34] MYERS RP,SWAIN MG,LEE SS,et al. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid[J]. Am J Gastroenterol,2013,108(6):933-941.

施引文献

资源附件(0)

访问统计